Latest Insider Transactions at Ironwood Pharmaceuticals Inc (IRWD)
This section provides a real-time view of insider transactions for Ironwood Pharmaceuticals Inc (IRWD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IRONWOOD PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IRONWOOD PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2022
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
48,424
-1.96%
|
$484,240
$10.77 P/Share
|
|
Feb 28
2022
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,238
-1.19%
|
$22,380
$10.77 P/Share
|
|
Jan 19
2022
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,290
+8.67%
|
-
|
|
Jan 19
2022
|
Jason Rickard SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,174
+9.22%
|
-
|
|
Jan 19
2022
|
Michael Shetzline SVP, CMO, Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
29,326
+12.1%
|
-
|
|
Dec 22
2021
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
46,327
-7.46%
|
$509,597
$11.41 P/Share
|
|
Dec 16
2021
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
27,000
-7.78%
|
$297,000
$11.28 P/Share
|
|
Dec 15
2021
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
1,541
+1.98%
|
-
|
|
Dec 15
2021
|
Andrew Dreyfus |
BUY
Grant, award, or other acquisition
|
Direct |
1,431
+1.09%
|
-
|
|
Dec 15
2021
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,211
+1.82%
|
-
|
|
Dec 14
2021
|
Julie Mc Hugh |
SELL
Open market or private sale
|
Direct |
10,000
-6.74%
|
$110,000
$11.02 P/Share
|
|
Dec 06
2021
|
Sravan Kumar Emany SVP, COO and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+50.0%
|
-
|
|
Nov 23
2021
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,462
-1.17%
|
$16,082
$11.58 P/Share
|
|
Nov 23
2021
|
Michael Shetzline SVP, CMO, Head-Res&Drug |
SELL
Open market or private sale
|
Direct |
13,776
-6.98%
|
$151,536
$11.58 P/Share
|
|
Nov 23
2021
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
17,193
-2.38%
|
$189,123
$11.58 P/Share
|
|
Nov 23
2021
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
52,644
-7.84%
|
$579,084
$11.58 P/Share
|
|
Sep 15
2021
|
Andrew Dreyfus |
BUY
Grant, award, or other acquisition
|
Direct |
1,344
+0.99%
|
-
|
|
Sep 15
2021
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
1,447
+1.9%
|
-
|
|
Sep 15
2021
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,137
+1.74%
|
-
|
|
Aug 16
2021
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
680
-0.19%
|
$8,840
$13.48 P/Share
|
|
Aug 16
2021
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
567
-0.9%
|
$7,371
$13.48 P/Share
|
|
Aug 02
2021
|
Minardo John Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
79,892
+50.0%
|
-
|
|
Jul 20
2021
|
Ronald Silver Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+24.03%
|
-
|
|
Jun 15
2021
|
Andrew Dreyfus |
BUY
Grant, award, or other acquisition
|
Direct |
1,453
+1.08%
|
-
|
|
Jun 15
2021
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
1,565
+2.09%
|
-
|
|
Jun 15
2021
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,229
+1.91%
|
-
|
|
Jun 14
2021
|
Mark G Currie |
SELL
Open market or private sale
|
Direct |
23,571
-3.97%
|
$259,281
$11.59 P/Share
|
|
Jun 07
2021
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
104,690
+13.49%
|
-
|
|
Jun 02
2021
|
Mark G Currie |
BUY
Grant, award, or other acquisition
|
Direct |
22,766
+3.69%
|
-
|
|
Jun 02
2021
|
Andrew Dreyfus |
BUY
Grant, award, or other acquisition
|
Direct |
22,766
+14.72%
|
-
|
|
Jun 02
2021
|
Jon R Duane |
BUY
Grant, award, or other acquisition
|
Direct |
22,766
+24.49%
|
-
|
|
Jun 02
2021
|
Marla L Kessler |
BUY
Grant, award, or other acquisition
|
Direct |
22,766
+24.49%
|
-
|
|
Jun 02
2021
|
Julie Mc Hugh |
BUY
Grant, award, or other acquisition
|
Direct |
22,766
+13.3%
|
-
|
|
Jun 02
2021
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
22,766
+24.08%
|
-
|
|
Jun 02
2021
|
Lawrence S Olanoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,766
+19.94%
|
-
|
|
Jun 02
2021
|
Edward P Owens Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,766
+8.61%
|
-
|
|
Jun 02
2021
|
Jay Shepard |
BUY
Grant, award, or other acquisition
|
Direct |
22,766
+28.08%
|
-
|
|
Jun 02
2021
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
22,766
+26.91%
|
-
|
|
May 24
2021
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,716
-0.3%
|
$20,592
$12.25 P/Share
|
|
May 24
2021
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
516
-0.14%
|
$6,192
$12.25 P/Share
|
|
May 24
2021
|
Michael Shetzline SVP, CMO, Head-Res&Drug |
SELL
Open market or private sale
|
Direct |
2,077
-1.04%
|
$24,924
$12.25 P/Share
|
|
Apr 20
2021
|
Julie Mc Hugh |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+1.95%
|
-
|
|
Mar 26
2021
|
Gina Consylman SVP, CFO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
56,372
+12.56%
|
-
|
|
Mar 26
2021
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,638
+14.54%
|
-
|
|
Mar 26
2021
|
Jason Rickard SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,372
+13.44%
|
-
|
|
Mar 26
2021
|
Michael Shetzline SVP, CMO, Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
38,655
+16.23%
|
-
|
|
Mar 15
2021
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
1,573
+3.11%
|
-
|
|
Mar 15
2021
|
Andrew Dreyfus |
BUY
Grant, award, or other acquisition
|
Direct |
1,460
+1.32%
|
-
|
|
Mar 15
2021
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,235
+3.06%
|
-
|
|
Mar 10
2021
|
Alexander J Denner |
BUY
Open market or private purchase
|
Indirect |
75,000
+0.46%
|
$750,000
$10.54 P/Share
|